FierceBiotech

VectorY pens $1.2B biobucks pact to use Shape's capsid to deliver gene therapies into brain

VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain. The Dutch biotech has secured an exclusive option to evaluate ...
Hosted on MSN

VectorY enters agreement with Shape Therapeutics for AAV capsid

VectorY Therapeutics has signed an agreement securing an exclusive option to assess Shape Therapeutics’ SHP-DB1 adeno-associated virus (AAV) capsid for vectorised antibody payloads targeting three ...
Business Wire

VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

AMSTERDAM & BOSTON & SEATTLE--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and ...
GEN

Single-Assay Evaluation of AAV Capsid Quality: Novel Digital PCR Approaches Advance Gene Therapy Research and Production

Gene therapy (introducing genetic material into living cells to fix, replace, enhance, or block a faulty gene) is rapidly gaining traction as a strategy for the treatment of genetic diseases. The ...